GenesWell - Model ddEGFR - Mutation Test Kit
Chemotherapy drugs have many side effects such as reduction in white blood cells, hair loss, vomiting because they attack rapidly growing cells without separating cancer cells from normal cells. However targeted therapy drugs have less side effects because they detect and attack specific targets that exist only in cancer cells.
Product Details
The GenesWell ddEGFR Mutation Test is a companion diagnostics which detects 45 EGFR mutations for non-small cell lung cancer(NSCLC) patients. It selects which NSCLC patients will respond to tyrosine kinase inhibitors such as Tarceva®(Erlotinib) and Tagrisso™(Osimertinib)
Traditional Treatment
- Prescribe various chemotherapy drugs sequentially without companion diagnostic test
Companion Diagnostics / Targeted therapy
- A customized prescription based on genetic information of the patient
- High treatment effects and fewer side effects
Companion diagnostics is an advanced diagnostic test that identifies the patient's genetic information and selects patients who are either effective in a particular treatment or unable to receive treatment due to the risk of severe abnormalities.
PCR(Polymerase Chain Reaction) techniques, which are techniques for amplifying/detecting genetic material, are consistently evolving. Especially ddPCR(digital droplet PCR)* technique, an advanced PCR platform, analyzes target genes after gene amplification with sample DNA partitioned across 20,000 droplets.
Proces
- DNA extraction from cancer tissue(FFPE)
- GenesWell ddEGFR Mutation Test kit
- ddPCR
- Analysis software
Highlights
- Selection of patients who need targeted anti-cancer therapy
- Available for low frequency(0.8%) mutations
- ddPCR platform with high sensitivity
- Software for automated result analysis
Customer reviews
No reviews were found for GenesWell - Model ddEGFR - Mutation Test Kit. Be the first to review!